

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shenzhen International Holdings Limited
深圳國際控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 00152)

**(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
(2) CHANGE OF COMPOSITION OF
SPECIALISED COMMITTEES OF THE BOARD**

The Board announces that, with effect from 1 September 2022, (i) Dr. Wang Guowen has been appointed as an Independent Non-executive Director, a member of each of the Audit Committee and the Remuneration and Appraisal Committee; and (ii) Professor Cheng Tai Chiu, Edwin resigned from his position as an Independent Non-executive Director, a member of each of the Audit Committee and the Remuneration and Appraisal Committee.

(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Shenzhen International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from 1 September 2022, (i) Dr. Wang Guowen (“**Dr. Wang**”) has been appointed as an independent non-executive director of the Company (the “**Independent Non-executive Director**”), a member of each of the audit committee of the Company (the “**Audit Committee**”) and the remuneration and appraisal committee of the Company (the “**Remuneration and Appraisal Committee**”); and (ii) Professor Cheng Tai Chiu, Edwin (“**Professor Cheng**”) resigned from his position as an Independent Non-executive Director, a member of each of the Audit Committee and the Remuneration and Appraisal Committee, as he intends to devote more time to focus on his other work commitments.

Professor Cheng has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The biographical details of Dr. Wang are as follows:

Dr. Wang, aged 56, holds a doctoral degree in World Economics from Nankai University and completed post-doctoral research in supply chain management in Peking University. Dr. Wang is a Senior Research Fellow of, and the Director of the Center for Logistics and Supply Chain Management at, the China (Shenzhen) Development Institute. He is also the Vice President of China Society of Logistics, Chief Representative of the China Round-table of the Council of Supply Chain Management Professionals, the Chairman of the Expert Committee on Blockchain Application in Logistics and Supply Chain under the China Federation of Logistics & Purchasing ("CFLP"), and the Chairman of the CFLP Green Logistics Expert Committee, as well as a visiting professor of Nankai University, Beijing Jiaotong University and The Hong Kong Polytechnic University. From January 2013 to December 2019, Dr. Wang was an independent non-executive director of Shenzhen Feima International Supply Chain Co Ltd (the shares of which are listed on the Shenzhen Stock Exchange (Stock Code: 002210)). Dr. Wang previously served as an expert to World Bank and Asia Development Bank, and the Chinese industry convener of APEC Asia-Pacific Supply Chain Consortium (A2C2). He was awarded the title of "Top 30 Logistics Expert in China" by CFLP, and "Top 40 Logistics and Transportation Expert in China" by the China Communications and Transportation Association in 2018. Dr. Wang has extensive experience in regional economy, industrial development planning, logistics and supply chain management.

Dr. Wang has entered into a service contract with the Company for a term of three years commencing on 1 September 2022 and is subject to retirement by rotation but is eligible for re-election at the annual general meeting of the Company in accordance with the bye-laws of the Company. Dr. Wang is entitled to receiving an annual director's fee of HK\$350,000, which is determined by the Board based on the recommendation of the Remuneration and Appraisal Committee with reference to the estimated time to be spent by him on the Company's matters.

Save as disclosed above and as at the date of this announcement, Dr. Wang:

- (i) does not hold and has not held any directorships in other listed public companies in the last three years;
- (ii) does not hold and has not held any position with the Company and/or its subsidiaries;
- (iii) does not have any relationship with any directors, senior management, substantial shareholders and/or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company; and
- (iv) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Company considers that in relation to the appointment of Dr. Wang as an Independent Non-executive Director, there is no other information which is discloseable nor is he involved in any of the matters required to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his appointment which needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to extend its heartfelt gratitude to Professor Cheng for his valuable contribution to the Group and would like to welcome Dr. Wang to the Board.

(2) CHANGE OF COMPOSITION OF SPECIALISED COMMITTEES OF THE BOARD

As a result of the change of the composition of the Audit Committee and the Remuneration and Appraisal Committee mentioned in (1) above, with effect from 1 September 2022, (i) the Audit Committee comprises Dr. Zeng Zhi (Chairman), Mr. Pan Chaojin and Dr. Wang; and (ii) the Remuneration and Appraisal Committee comprises Mr. Pan Chaojin (Chairman), Mr. Li Haitao and Dr. Wang.

By Order of the Board
Shenzhen International Holdings Limited
Liu Wangxin
Joint Company Secretary

1 September 2022

As at the date of this announcement, the Board consists of Messrs. Li Haitao, Liu Zhengyu, Wang Peihang and Dr. Dai Jingming as executive directors, Mr. Hu Wei and Dr. Zhou Zhiwei as non-executive directors and Mr. Pan Chaojin, Dr. Zeng Zhi and Dr. Wang Guowen as independent non-executive directors.